Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.65 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.58 |
| ▸ | STRADA | Q7RTN6 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31079640 | 0.89 | MAPK14 (0.67) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL29594719 | 0.86 | MAPK14 (0.64) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL5862045 | 0.86 | MAPK14 (0.64) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL4383268 | 0.84 | MAPK14 (0.72) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| Hydrochloric Acid SCHEMBL4374131 | 0.83 | MAPK14 (0.71) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| Hydrochloric Acid SCHEMBL29594457 | 0.83 | MAPK14 (0.71) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL13602988 | 0.82 | MAPK14 (0.75) | MAPK14 | |
| SCHEMBL27765711 | 0.80 | MAPK14 (0.79) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL4376204 | 0.79 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL29593900 | 0.78 | MAPK14 (0.80) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114748622-B | P38 kinase inhibitors reduce DUX4 and downstream gene expression and treat FSHD | 弗尔康医疗公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-114732910-B | P38 kinase inhibitors reduce DUX4 and downstream gene expression and treat FSHD | 弗尔康医疗公司 | 2024-08-23 | — | — | CN | disclosed |